Updates in the Systemic Therapy Options for Clear and Non-Clear Cell Renal Cell Carcinoma
The expansion of treatment options included in the treatment guidelines has certainly improved outcomes of patients with advanced renal cell cancer (RCC) but presents numerous clinical challenges, such as determining best choice of primary treatment for a given patient based on tumor biology and clinical characteristics and in choosing appropriate subsequent lines of treatment. To offer optimal care to patients with RCC, clinicians have a must have a deep understanding of the key trial results and know how to best contextualize evidence to optimize considerations at key decision points along the RCC treatment continuum. In addition, due to rare occurrences of non-clear cell RCC cases, there is limited data to help inform practitioners about the management of these tumors. It may be helpful to discuss the updated data/evidence supporting the NCCN panel’s recommendations in this setting.
Target Audience
This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.
Learning Objectives
Following this program, participants should be able to:
- Review clinical data on established therapies for patients with metastatic renal cell carcinoma.
- Strategize the selection of optimal first-line and subsequent-line therapies based on patient and tumor characteristics.
- Evaluate strategies to effectively manage the non-clear cell histology of renal cell carcinoma at advanced stages.
Eric Jonasch, MD
The University of Texas MD Anderson Cancer Center
Peter A. Johnstone, MD
Moffitt Cancer Center
Philippe E. Spiess, MD, MS
Moffitt Cancer Center
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
The faculty listed below have no relevant financial relationships with ineligible companies to disclose.
Peter A. Johnstone, MD
Philippe E. Spiess, MD, MS
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Eric Jonasch, MD
Aravive: Consulting Fee
Arrowhead Pharmaceuticals, Inc.: Grant/Research Support
AVEO Pharmaceuticals, Inc.: Consulting Fee
Calithera Biosciences, Inc.: Consulting Fee
Eisai Inc.: Consulting Fee
Exelixis Inc.: Consulting Fee
Ipsen: Consulting Fee
Merck & Co., Inc.: Consulting Fee; Grant/Research Support
NiKang Therapeutics, Inc.: Consulting Fee; Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Consulting Fee
NCCN Staff Disclosures
The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Crystal S. Denlinger, MD
Agios, Inc.: Grant/Research Support
Amgen Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support
BeiGene: Scientific Advisor; Grant/Research Support
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Grant/Research Support
Genmab: Grant/Research Support
MacroGenics: Grant/Research Support
MedImmune Inc: Grant/Research Support
Merck & Co., Inc.: Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor
Zymeworks: Scientific Advisor; Grant/Research Support
Taneal Carter
Johnson & Johnson: Equity Interest/Stock Options
None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour, 1.0 of which are pharmacotherapeutic contact hours.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-23-058-H01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until March 1, 2024. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 ANCC Pharmacology Contact Hours
- 1.00 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing